RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site

RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. Here, we identify two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleot...

Descripción completa

Detalles Bibliográficos
Autores principales: Haza, Katarzyna Z., Martin, Heather L., Rao, Ajinkya, Turner, Amy L., Saunders, Sophie E., Petersen, Britta, Tiede, Christian, Tipping, Kevin, Tang, Anna A., Ajayi, Modupe, Taylor, Thomas, Harvey, Maia, Fishwick, Keri M., Adams, Thomas L., Gaule, Thembaninkosi G., Trinh, Chi H., Johnson, Matthew, Breeze, Alexander L., Edwards, Thomas A., McPherson, Michael J., Tomlinson, Darren C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245420/
https://www.ncbi.nlm.nih.gov/pubmed/34193876
http://dx.doi.org/10.1038/s41467-021-24316-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245420/
https://www.ncbi.nlm.nih.gov/pubmed/34193876
http://dx.doi.org/10.1038/s41467-021-24316-0

Ejemplares similares